Abstract
Purpose
The suitability of [18F]FDG, [18F]FLT, [18F]FET, and [18F]FCH as non-invasive positron emission tomography (PET) biomarkers for monitoring response to chemotherapy was analyzed in various experimental tumor models.
Procedures
Tracer uptake into three syngeneic rodent tumor models and ten human xenograft models was evaluated using semiquantitative analysis of small-animal PET data. Murine RIF-1 fibrosarcomas and [18F]FLT were selected to monitor the effects of the novel cytotoxic patupilone.
Results
Except [18F]FCH, all tracers provided good tumor visualization. Highest [18F]FDG uptake was identified in syngeneic tumors. Xenograft models, however, showed low [18F]FDG SUVs and were better visualized by [18F]FLT. Monitoring the effects of patupilone on [18F]FLT uptake in RIF-1 tumors revealed a significant decrease of tracer uptake after 24 h, which strongly negatively correlated with apoptosis.
Conclusion
[18F]FLT PET of experimental tumors is a viable complement to [18F]FDG for preclinical drug development. [18F]FLT may be an excellent biomarker for patupilone-induced apoptosis.
Similar content being viewed by others
References
Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 97:9226–9233
Di Chiro G, De La Paz RL, Brooks RA et al (1982) Glucose utilization of cerebral gliomas measured by [18F]fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329
Hicks RJ, Kalff V, MacManus MP et al (2001) 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596–1604
Weber WA (2005) Use of PET monitoring cancer therapy and for predicting outcome. J Nucl Med 46:983–995
Lammertsma AA, Hoekstra CJ, Giaccone G et al (2006) How should we analyse FDG PET studies for monitoring tumour response. Eur J Nucl Med Mol Imaging 33:16–21
Kenny LM, Aboagye EO, Price RM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Onc 16:176–185
Spaeth N, Wyss MT, Weber B et al (2004) Uptake of 18F-fluorocholine, 18F-fluoroethyl-l-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumour recurrence. J Nucl Med 45:1931–1938
Katz-Brull R, Degani H (1996) Kinetics of choline transport and phosphorylation in human breast cancer cells: NMR application of the zero trans method. Anticancer Res 16:1375–1380
Belt JA, Marina NM, Phelps DA et al (1993) Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul 33:235–252
Kong W, Engel K, Wang J (2004) Mammalian nucleoside transporters. Curr Drug Metab 5:63–84
Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336
Grierson JR, Shields AF (2000) Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27:143–156
Rasey JS, Grierson JR, Wiens LW et al (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 438:1210–1217
Buck AK, Halter G, Schirrmeister H et al (2003) Imaging proliferation in lung tumours with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44:1432–1434
Mier W, Haberkorn U, Eisenhut M (2002) [18F]FLT; portrait of a proliferation marker. Eur J Nucl Med 29:165–169
Shields AF (2006) Positron emission tomography measurement of tumour metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8:141–150
Kenny LM, Aboagye EO, Price PM (2004) Positron emission tomography imaging of cell proliferation in oncology. Clin Oncol 16:176–185
Heiss P, Mayer S, Herz M et al (1999) Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-l-tyrosine in vitro and in vivo. J Nucl Med 40:1367–1373
Wester HJ, Herz M, Weber W et al (1999) Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-l-tyrosine for tumour imaging. J Nucl Med 40:205–212
Pauleit D, Stoffels G, Schaden W et al (2005) PET with O-(2-18F-fluoroethyl)-l-tyrosine in peripheral tumours: first clinical results. J Nucl Med 46:411–416
Langen KJ, Hamacher K, Weckesser M et al (2006) O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294
Wyss MT, Spaeth N, Biollaz G et al (2007) Uptake of 18F-fluorocholine, 18F-FET, and 18F-FDG in C6 gliomas and correlation with 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 48:608–614
Wang HE, Wu SY, Chang CW et al (2005) Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumour-bearing animal model. Nucl Med Biol 32:367–375
Rau FC, Weber WA, Wester HJ et al (2002) O-(2-[18F]fluoroethyl)-l-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. J Nucl Med 29:1039–1046
DeGrado TR, Baldwin SW, Wang S et al (2001) Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42:1805–1814
Price DT, Coleman RE, Liao RP et al (2002) Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168:273–280
Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990–995
Shinoura N, Nishijima M, Hara T et al (1997) Brain tumours: detection with C-11 choline PET. Radiology 202:497–503
Hara T, Inagaki K, Kosaka N et al (2000) Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 41:1507–1513
Hara T, Bansal A, DeGrado TR (2006) Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 5:498–509
McSheehy PMJ Allegrini PR Ametamey SM et al (2005) The anticancer agent RAD001 rapidly inhibits 18F-FDG uptake by sensitive but not resistant tumours. 52nd Meeting Society Nuclear Medicine, abstract 1238
Altmann K-H (2003) Epothilone B and its analogs—a new family of anticancer agents. Mini Rev Med Chem 3:149–158
Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. J Clin Oncol 22:2015–2025
Ferretti S, Allegrini PR, O’Reilly T et al (2005) Patupilone induced vascular disruption in orthotopic rodent tumour models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 11:7773–7784
Leyton J, Latigo JR, Perumal M et al (2005) Early detection of tumour response to chemotherapy by 3′-deoxy-3′[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumour model in vivo. Cancer Res 65:4202–4010
Kim WD, Ahn D, Oh Y et al (2006) New class of SN2 reactions catalyzed by protic solvents: facile fluorination for isotopic labeling of diagnostic molecules. J Am Chem Soc 128:16394–16397
Rudin M, McSheehy PMJ, Allegrini PR et al (2005) PTK787/ZK222584, a tyrosine kinase inhibitor of vascularendothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed 18:308–332
Missimer J, Madi Z, Honer M et al (2004) Performance evaluation of the 16-module quad-HIDAC small animal PET camera. Phys Med Biol 49:2069–2081
Jeavons AP, Chandler RA, Dettmar CAR (1999) A 3D HIDAC-PET camera with submillimetre resolution for imaging small animals. IEEE Trans Nucl Sci 46:468–473
Reader AJ, Erlandsson K, Flower MA et al (1998) Fast accurate iterative reconstruction for low-statistics positron volume imaging. Phys Med Biol 43:835–846
Mikolajczyk K, Szabatin M, Rudnicki P et al (1998) A JAVA environment for medical image data analysis: initial application for brain PET quantification. Med Inform (Lond) 23:207–214
O’Reilly T, Wartmann M, Brueggen J et al (2009) Pharmacokinetic profile of the novel microtubule stabilizer patupilone in tumour-bearing rodents and comparison of anti-cancer activity with other MTS in multi-drug resistant human colon tumour cells in vitro and in vivo. Cancer Chemother. Pharmacol 62(6):1045–1054
McSheehy PMJ, Robinson S, Ojugo A et al (1998) Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic RIF-1 tumours: a magnetic resonance study in vivo. Cancer Res 58:1185–1194
Lee L, Sharma S, Morgan B et al (2006) Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastases model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 7:761–771
Robinson S, Rijken P, Howe F et al (2003) Assessment of tumour vascular development and function by susceptibility MRI methods and immunohistochemistry. J Magn Res 17:445–454
Cooper RA, Carrington BM, Loncaster JA et al (2000) Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 57:53–59
Rajendran JG, Mankoff DA, O’Sullivan F et al (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245–2252
Fueger BJ, Czernin J, Hildebrandt I et al (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47:999–1006
Lee K-H, Ko B-H, Paik J-Y et al (2005) Effects of anesthetic agents and fasting duration on 18F-FDG biodistribution and insulin levels in tumor-bearing mice. J Nucl Med 46:1531–1536
Apisarnthanarax S, Alauddin MM, Mourtada F et al (2006) Early detection of chemoradioresponse in esophageal carcinoma by 3′-Deoxy-3′-3H-fluorothymidine using preclinical tumour models. Clin Cancer Res 12:4590–4597
Landberg G, Tan EM, Roos G (1990) Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. Exp Cell Res 187(1):111–118
Quiñones-Hinojosa A, Sanai N, Smith JS (2005) Techniques to assess the proliferative potential of brain tumours. J Neurooncol 74:19–30
Eriksson S, Kierdaszuk B, Munch-Petersen B et al (1991) Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 176:586–592
Acknowledgments
The authors thank the team of Rolf Hesselmann and colleagues (PET Center, Division of Nuclear Medicine at University Hospital Zurich) for [18F]FET and [18F]FCH production.
Author information
Authors and Affiliations
Corresponding author
Additional information
T. Ebenhan and M. Honer contributed equally to this work.
An erratum to this article can be found at http://dx.doi.org/10.1007/s11307-009-0246-8
Rights and permissions
About this article
Cite this article
Ebenhan, T., Honer, M., Ametamey, S. et al. Comparison of [18F]-Tracers in Various Experimental Tumor Models by PET Imaging and Identification of an Early Response Biomarker for the Novel Microtubule Stabilizer Patupilone. Mol Imaging Biol 11, 308–321 (2009). https://doi.org/10.1007/s11307-009-0216-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-009-0216-1